scholarly article | Q13442814 |
P2093 | author name string | Diane Kleinermans | |
Don Nichols | |||
Lynn Purkins | |||
Nolan Wood | |||
P2860 | cites work | Drug interactions with fluconazole | Q68764002 |
Comparative effects of H2-receptor antagonists on drug interaction in rats | Q69890035 | ||
Current and emerging azole antifungal agents | Q24550733 | ||
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. | Q28379300 | ||
Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists | Q33860341 | ||
Voriconazole, a novel wide‐spectrum triazole: oral pharmacokinetics and safety | Q35825582 | ||
The clinical importance of drug interactions with antiulcer therapy | Q37998709 | ||
Review of fluconazole: a new triazole antifungal agent | Q38308672 | ||
The search for new triazole antifungal agents | Q40884177 | ||
Characterization of cimetidine, ranitidine, and related structures' interaction with cytochrome P-450 | Q42241875 | ||
Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus | Q42538222 | ||
Determination of a new antifungal agent, voriconazole, by multidimensional high-performance liquid chromatography with direct plasma injection onto a size-exclusion column | Q47310345 | ||
Voriconazole: A second-generation triazole | Q47865467 | ||
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacology | Q128406 |
P304 | page(s) | 51-55 | |
P577 | publication date | 2003-12-01 | |
P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
P1476 | title | Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole | |
Histamine H2‐receptor antagonists have no clinically significant effect on the steady‐state pharmacokinetics of voriconazole | |||
P478 | volume | 56 Suppl 1 |
Q37144774 | Accelerated metabolism of voriconazole and its partial reversal by cimetidine |
Q38015710 | Azole interactions with multidrug therapy in pediatric oncology |
Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
Q38284468 | Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. |
Q42218014 | Disseminated Scedosporium prolificans infection in an 'extensive metaboliser': navigating the minefield of drug interactions and pharmacogenomics. |
Q36429699 | Drug interactions during therapy with three major groups of antimicrobial agents |
Q33726698 | Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. |
Q42173355 | Inhibition of voriconazole metabolism by chloramphenicol in an adolescent with central nervous system aspergillosis |
Q37775009 | Management of drug and food interactions with azole antifungal agents in transplant recipients |
Q37892536 | Pharmacogenomics of the triazole antifungal agent voriconazole |
Q46807629 | Safety and pharmacokinetics of coadministered voriconazole and anidulafungin |
Q37331953 | The enzymatic basis of drug-drug interactions with systemic triazole antifungals. |
Q34034599 | Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity |
Q37964703 | Triazole antifungal agents in invasive fungal infections: a comparative review |